News

The FPS Health and the FAMHP invite you to participate in the public consultation on a clinical trial with the genetically modified medicinal product Talimogene Laherparepvec from the company Amgen. The purpose of this trial is to determine the safety and efficacy of talimogene laherparepvec in pediatric subjects with advanced non-central nervous system (CNS) tumors that are amenable to direct injection. The public consultation runs from 24 March to 24 April 2019 inclusive.

After successful consideration among the FAMHP, the National Institute for Health and Disability Insurance (RIZIV-INAMI) and the manufacturer Therabel, the manufacturer has decided to continue to produce the drug Marevan. The FAMHP calls on pharmacists and patients to not order unnecessary inventories of the drug so that the drug will remain available for all patients.

The European Falsified Medications Directive came into effect on February 9, 2019. From that time most of the prescription and reimbursable medicines on the market must bear safety features. At each link in the distribution chain, the safety features must be checked so that the authenticity of the medicine upon delivery can be guaranteed.

Last updated on 29/06/2017